Compare WT & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WT | GPCR |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2011 | 2023 |
| Metric | WT | GPCR |
|---|---|---|
| Price | $20.67 | $47.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $17.67 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 3.1M | 808.9K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ 127.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $493,753,000.00 | N/A |
| Revenue This Year | $35.04 | N/A |
| Revenue Next Year | $8.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.43 | N/A |
| 52 Week Low | $10.69 | $15.80 |
| 52 Week High | $20.37 | $94.90 |
| Indicator | WT | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 67.12 | 46.46 |
| Support Level | $15.86 | $42.72 |
| Resistance Level | N/A | $57.15 |
| Average True Range (ATR) | 0.73 | 2.95 |
| MACD | 0.24 | -1.03 |
| Stochastic Oscillator | 97.67 | 20.29 |
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.